In the last few weeks three major joint ventures have been announced between international pharma’s and Chinese pharma’s. Merck & Co. will be working with Simcere, Pfizer is partnering with Hisun while AstraZeneca will be working with WuXi Appatec to develop and commercialize MEDI5117, a biologic for rheumatoid arthritis.
Giving us an insight into both big pharma and China will be AstraZeneca’s head of the China Biologics Innovation Center Jaiwen Han at Biologics World China 2012.
Biologics World China 2012 will be held on 5-7 November 2012 at Radisson Blu Hotel Pudong Century Park in Shanghai, China.
Organizations that are already confirmed attending include:
• 3S Bio
• Acertus Pharma LLC
• Bayer Pharma
• BD Bioscience
• Beijing Mab-Works
• Beijing Triprime Genetic Engineering Co. Ltd.
• Boehringer Ingelheim
• Bristol-Myers Squibb
• China Biologic Products
• Chinese-Taipei Biotechnology Service Association
• Gan&Lee Pharmaceuticals
• Genor BioPharma
• Huabei Organization New Drug Development Company
• HUYA Bioscience International
• Innovent Biologics
• Jiangsu Simcere Pharmaceutical R&D Co. Ltd
• June He Law Offices
• King Lai
• Merck & Co.
• Merck Millipore
Be heard, be seen by China's biologics industry!
Limited sponsorship and exhibition opportunities
If you have technologies, services or consulting expertise to offer to China’s Biopharma industry, it's your opportunity to act now!
Sartorius Stedim Biotech, Merck Millipore, Boehringer Ingelheim, TAP Biosystems, King Lai and BD Bioscience are already on board to showcase their capabilities at Biologics World China 2012.
Don't be the one to miss out! This unique and targeted biologics platform will be your one stop solution to reach out to the booming Chinese biopharma market!
80% of the exhibition and sponsorship opportunities have been sold and only very few showcase opportunities left!